The goal of the Developmental Research Program in the Mayo Clinic SPORE in Multiple Myeloma is to support innovative, scientifically sound projects that investigate any area pertaining to translational myeloma research. Funding from this program will stimulate developmental research that incorporates techniques and theoretical approaches that may not have been previously utilized in myeloma research. In so doing it provides a mechanism by which the SPORE can increase the number of scientists and clinical investigators who are committed to translational myeloma research. The Developmental Research Program will encourage the development of suitable projects, coordinate project review and selection, make funding recommendations to the Executive Committee, and monitor research progress. We have requested $130,000 annually ($80,000 per year from the SPORE funds augmented by $50,000 per year in matching funds from the Mayo Clinic Cancer Center) for the Developmental Research Program.
We aim to provide research support to two to three projects per year for one year with a second year of support possible based on exceptional progress towards the stated aims of the project. The long term goal is to translate the findings generated by developmental projects into a reduction in the incidence and mortality rates of myeloma. Without the funding, infrastructure, and expertise of the SPORE projects and investigators, it will be unlikely that innovative developmental research projects of the kind we envision can be brought to fruition. Specifically, the primary goals of the Developmental Research Program are to: (1) encourage innovative translational studies that are promising and have the potential to improve outcome in myeloma and mature into independently funded projects; (2) foster extensive collaboration between basic science and clinical disciplines in translational research in myeloma in the context of the myeloma SPORE program; (3) encourage investigators to apply their research findings in other tumor types to translational research in myeloma and; (4)generate new hypotheses that can be tested and provide the foundation for future large-scale research projects or clinical trials in order to reduce myeloma incidence and mortality rates.

Public Health Relevance

The Developmental Research Program will support new and highly innovative approaches to treat multiple myeloma with the aim of improving overall survival and quality of life of myeloma patients. It is envisioned that these novel translational pilot projects in myeloma research would mature into full projects or other independent NIH grants as a result of seed-funding from the Developmental Research Program.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
1P50CA186781-01A1
Application #
8930237
Study Section
Special Emphasis Panel (ZCA1-RPRB-0 (M1))
Project Start
2015-09-01
Project End
2020-08-31
Budget Start
2015-09-01
Budget End
2016-08-31
Support Year
1
Fiscal Year
2015
Total Cost
$118,822
Indirect Cost
$27,138
Name
Mayo Clinic, Arizona
Department
Type
DUNS #
153665211
City
Scottsdale
State
AZ
Country
United States
Zip Code
85259
Baughn, Linda B; Pearce, Kathryn; Larson, Dirk et al. (2018) Differences in genomic abnormalities among African individuals with monoclonal gammopathies using calculated ancestry. Blood Cancer J 8:96
Russell, Stephen J; Barber, Glen N (2018) Oncolytic Viruses as Antigen-Agnostic Cancer Vaccines. Cancer Cell 33:599-605
Clay-Gilmour, Alyssa I; Kumar, Shaji; Rajkumar, S Vincent et al. (2018) Risk of MGUS in relatives of multiple myeloma cases by clinical and tumor characteristics. Leukemia :
Sidiqi, M Hasib; Aljama, Mohammed A; Muchtar, Eli et al. (2018) Light chain type predicts organ involvement and survival in AL amyloidosis patients receiving stem cell transplantation. Blood Adv 2:769-776
Nair, Shiny; Sng, Joel; Boddupalli, Chandra Sekhar et al. (2018) Antigen-mediated regulation in monoclonal gammopathies and myeloma. JCI Insight 3:
Msaouel, Pavlos; Opyrchal, Mateusz; Dispenzieri, Angela et al. (2018) Clinical Trials with Oncolytic Measles Virus: Current Status and Future Prospects. Curr Cancer Drug Targets 18:177-187
Go, Ronald S; Rajkumar, S Vincent (2018) How I manage monoclonal gammopathy of undetermined significance. Blood 131:163-173
Kyle, Robert A; Larson, Dirk R; McPhail, Ellen D et al. (2018) Fifty-Year Incidence of Waldenström Macroglobulinemia in Olmsted County, Minnesota, From 1961 Through 2010: A Population-Based Study With Complete Case Capture and Hematopathologic Review. Mayo Clin Proc 93:739-746
Calcinotto, Arianna; Brevi, Arianna; Chesi, Marta et al. (2018) Microbiota-driven interleukin-17-producing cells and eosinophils synergize to accelerate multiple myeloma progression. Nat Commun 9:4832
Facon, Thierry; Dimopoulos, Meletios A; Dispenzieri, Angela et al. (2018) Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma. Blood 131:301-310

Showing the most recent 10 out of 95 publications